Genomic landscape for tumours: Is there any evidence?

Photo by Jose Antonio Gallego Vu00e1zquez on Pexels.com There are numerous studies and I have highlighted the most pertinent aspects of the molecular landscape to bring you to speed. In one word-potential. Molecular amalgamation of the studies in clinic is time consuming, expensive and not standardised. Most important aspect of this paper? 10 gene signature … Continue reading Genomic landscape for tumours: Is there any evidence?

Is physician-reported data better than patient-reported outcomes? (Example of prostate cancer)

Reason for inclusion: An accurate assessment of treatment-related complications is missing in follow-ups. Practise changing statement: Physician assessment+ Patient report outcomes on a continuous basis will help more to define the extent of problems. We also need more quantitative measures. Page 1 specific information before the design of any particular research study. Patient-specific information may … Continue reading Is physician-reported data better than patient-reported outcomes? (Example of prostate cancer)